An Elaborate New Linker System Significantly Enhances the Efficacy of an HER2‐Antibody‐Drug Conjugate against Refractory HER2‐Positive Cancers

An Elaborate New Linker System Significantly Enhances the Efficacy of an HER2‐Antibody‐Drug Conjugate against Refractory HER2‐Positive Cancers

Abstract Human epidermal growth factor receptor 2 (HER2) is overexpressed in breast and gastric cancers and this causes poor clinical outcomes. Although both T‐DM1 and Enhertu are approved as an HER2‐targeting antibody‐drug conjugate (ADC), the effects of these drugs are still not satisfactory to er...

Full description

Bibliographic Details
Main Authors: Seol Hwa Shin, Yun‐Hee Park, Seok Soon Park, Eun Jin Ju, Jin Park, Eun Jung Ko, Dong Jun Bae, Sang‐Yeob Kim, Chul‐Woong Chung, Ho Young Song, Se Jin Jang, Seong‐Yun Jeong, Si Yeol Song, Eun Kyung Choi
Format: Article
Language:English
Published: Wiley 2021-12-01
Series:Advanced Science
Subjects:
antibody drug conjugate
HER2
patient derived xenograft (PDX)
Online Access:https://doi.org/10.1002/advs.202102414

Internet

https://doi.org/10.1002/advs.202102414

Similar Items